AAAAAA
Results:
1-9
|
Results: 9
Authors:
Sweetenham, JW
Santini, G
Qian, W
Guelfi, M
Schmitz, N
Simnett, S
Nagler, A
Holte, H
Kvaloy, S
Bruzzi, P
Goldstone, AH
Citation: Jw. Sweetenham et al., High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: Results of a randomized trial of the European group for blood and marrow transplantation and the United Kingdom lymphoma group, J CL ONCOL, 19(11), 2001, pp. 2927-2936
Authors:
Sweetenham, JW
Citation: Jw. Sweetenham, Stem cell transplantation for mantle cell lymphoma: should it ever be usedoutside clinical trials?, BONE MAR TR, 28(9), 2001, pp. 813-820
Authors:
George, P
Wyre, RM
Bruty, SJ
Sweetenham, JW
Duncombe, AS
Citation: P. George et al., Automated immature reticulocyte counts are early markers of engraftment following autologous PBSC transplantation in patients with lymphoma, J HEMATH ST, 9(2), 2000, pp. 219-223
Authors:
Crawley, CR
Foran, JM
Gupta, RK
Rohatiner, AZS
Summers, K
Matthews, J
Micallef, INM
Radford, JA
Johnson, SA
Johnson, PW
Sweetenham, JW
Lister, TA
Citation: Cr. Crawley et al., A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma, ANN ONCOL, 11(7), 2000, pp. 861-865
Authors:
Gale, J
Simmonds, PD
Mead, GM
Sweetenham, JW
Wright, DH
Citation: J. Gale et al., Enteropathy-type intestinal T-cell lymphoma: Clinical features and treatment of 31 patients in a single center, J CL ONCOL, 18(4), 2000, pp. 795-803
Authors:
Foran, JM
Gupta, RK
Cunningham, D
Popescu, RA
Goldstone, AH
Sweetenham, JW
Pettengell, R
Johnson, PWM
Bessell, E
Hancock, B
Summers, K
Hughes, J
Rohatiner, AZS
Lister, TA
Citation: Jm. Foran et al., A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response, BR J HAEM, 109(1), 2000, pp. 81-88
Authors:
Sweetenham, JW
Citation: Jw. Sweetenham, Economics of stem cell transplantation for lymphoma: counting the cost of living, BR J CANC, 82(1), 2000, pp. 4-6
Authors:
Sweetenham, JW
Smartt, PFM
Wilkins, BS
Pellatt, JC
Smith, JL
Ramsay, A
Whitehouse, JMA
Citation: Jw. Sweetenham et al., The clinical utility of the Revised European-American Lymphoma (REAL) Classification: Preliminary results of a prospective study in patients with non-Hodgkin's lymphoma from a single centre, ANN ONCOL, 10(9), 1999, pp. 1121-1124
Authors:
Sweetenham, JW
Carella, AM
Taghipour, G
Cunningham, D
Marcus, R
Della Volpe, A
Linch, DC
Schmitz, N
Goldstone, AH
Citation: Jw. Sweetenham et al., High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Group for Blood and Marrow Transplantation, J CL ONCOL, 17(10), 1999, pp. 3101-3109
Risultati:
1-9
|